GH Quote, Financials, Valuation and Earnings

Quest Diagnostics has a net margin of -46.77% compared to Guardant Health's net margin of 8.3%. Guardant Health's return on equity of -8518.58% beat Quest Diagnostics's return on equity of 13.14%.

Guardant Health has a consensus price target of $59.67, signalling upside risk potential of 24.82%. On the other hand Quest Diagnostics has an analysts' consensus of $184.10 which suggests that it could grow by 10.22%. Given that Guardant Health has higher upside potential than Quest Diagnostics, analysts believe Guardant Health is more attractive than Quest Diagnostics.

Guardant Health has a beta of 1.442, which suggesting that the stock is 44.2% more volatile than S&P 500. In comparison Quest Diagnostics has a beta of 0.492, suggesting its less volatile than the S&P 500 by 50.805%.

Guardant Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quest Diagnostics offers a yield of 1.86% to investors and pays a quarterly dividend of $0.80 per share. Guardant Health pays -- of its earnings as a dividend. Quest Diagnostics pays out 38% of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Guardant Health quarterly revenues are $203.5M, which are smaller than Quest Diagnostics quarterly revenues of $2.7B. Guardant Health's net income of -$95.2M is lower than Quest Diagnostics's net income of $220M. Notably, Guardant Health's price-to-earnings ratio is -- while Quest Diagnostics's PE ratio is 21.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health is 7.62x versus 1.87x for Quest Diagnostics. Usually stocks with elevated PS ratios are considered overvalued.

Exact Sciences has a net margin of -46.77% compared to Guardant Health's net margin of -14.32%. Guardant Health's return on equity of -8518.58% beat Exact Sciences's return on equity of -35.57%.

Guardant Health has a consensus price target of $59.67, signalling upside risk potential of 24.82%. On the other hand Exact Sciences has an analysts' consensus of $68.54 which suggests that it could grow by 27.7%. Given that Exact Sciences has higher upside potential than Guardant Health, analysts believe Exact Sciences is more attractive than Guardant Health.

Guardant Health has a beta of 1.442, which suggesting that the stock is 44.2% more volatile than S&P 500. In comparison Exact Sciences has a beta of 0.950, suggesting its less volatile than the S&P 500 by 5%.

Guardant Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

Guardant Health quarterly revenues are $203.5M, which are smaller than Exact Sciences quarterly revenues of $706.8M. Guardant Health's net income of -$95.2M is higher than Exact Sciences's net income of -$101.2M. Notably, Guardant Health's price-to-earnings ratio is -- while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health is 7.62x versus 3.52x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Labcorp Holdings has a net margin of -46.77% compared to Guardant Health's net margin of 6.36%. Guardant Health's return on equity of -8518.58% beat Labcorp Holdings's return on equity of 9.01%.

Guardant Health has a consensus price target of $59.67, signalling upside risk potential of 24.82%. On the other hand Labcorp Holdings has an analysts' consensus of $279.06 which suggests that it could grow by 13.45%. Given that Guardant Health has higher upside potential than Labcorp Holdings, analysts believe Guardant Health is more attractive than Labcorp Holdings.

Guardant Health has a beta of 1.442, which suggesting that the stock is 44.2% more volatile than S&P 500. In comparison Labcorp Holdings has a beta of 0.819, suggesting its less volatile than the S&P 500 by 18.086%.

Guardant Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Labcorp Holdings offers a yield of 1.17% to investors and pays a quarterly dividend of $0.72 per share. Guardant Health pays -- of its earnings as a dividend. Labcorp Holdings pays out 32.59% of its earnings as a dividend. Labcorp Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Guardant Health quarterly revenues are $203.5M, which are smaller than Labcorp Holdings quarterly revenues of $3.3B. Guardant Health's net income of -$95.2M is lower than Labcorp Holdings's net income of $212.8M. Notably, Guardant Health's price-to-earnings ratio is -- while Labcorp Holdings's PE ratio is 28.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health is 7.62x versus 1.57x for Labcorp Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Natera has a net margin of -46.77% compared to Guardant Health's net margin of -13.34%. Guardant Health's return on equity of -8518.58% beat Natera's return on equity of -19.19%.

Guardant Health has a consensus price target of $59.67, signalling upside risk potential of 24.82%. On the other hand Natera has an analysts' consensus of $192.78 which suggests that it could grow by 29.91%. Given that Natera has higher upside potential than Guardant Health, analysts believe Natera is more attractive than Guardant Health.

Guardant Health has a beta of 1.442, which suggesting that the stock is 44.2% more volatile than S&P 500. In comparison Natera has a beta of 1.729, suggesting its more volatile than the S&P 500 by 72.907%.

Guardant Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Natera offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health pays -- of its earnings as a dividend. Natera pays out -- of its earnings as a dividend.

Guardant Health quarterly revenues are $203.5M, which are smaller than Natera quarterly revenues of $501.8M. Guardant Health's net income of -$95.2M is lower than Natera's net income of -$66.9M. Notably, Guardant Health's price-to-earnings ratio is -- while Natera's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health is 7.62x versus 10.39x for Natera. Usually stocks with elevated PS ratios are considered overvalued.